MedVellum
MedVellum
Back to Library

Sickle Cell Crisis

On This Page

Overview

Sickle Cell Crisis

Quick Reference

Critical Alerts

  • Acute Chest Syndrome (ACS) is life-threatening: New infiltrate + respiratory symptoms
  • Fever in SCD = Medical emergency: Functional asplenia → overwhelming sepsis
  • Opioids are appropriate for pain crisis: Do not undertreat pain
  • Exchange transfusion for severe ACS, stroke, multi-organ failure: Simple transfusion may not be enough
  • Think stroke in any neurological change: Low threshold for imaging
  • Splenic sequestration can cause rapid death: Especially in children

Key Diagnostics

TestFindingSignificance
CBCLow Hgb, elevated reticulocytesBaseline hemolysis
Reticulocyte countMay be low (aplastic crisis) or highErythropoiesis status
CXRNew infiltrateAcute chest syndrome
Type and screenBlood availabilityTransfusion preparation
Pulse oximetryHypoxiaACS or PE
Blood culturesIf febrileRule out sepsis

Emergency Treatments

ConditionTreatmentDetails
Pain crisisIV opioids (morphine, hydromorphone)Titrate to pain relief
ACSO2, antibiotics, transfusion, bronchodilatorsICU if severe
Fever (>8.5°C)Empiric antibioticsCeftriaxone + cover atypicals
StrokeExchange transfusionTarget HbS <30%
Aplastic crisisTransfusionCorrect anemia
Splenic sequestrationTransfusionUrgent volume/RBC replacement

Definition

Overview

Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a single nucleotide mutation resulting in abnormal hemoglobin (HbS) that polymerizes under low oxygen conditions, causing red blood cells to become rigid and sickle-shaped. This leads to vaso-occlusion, hemolysis, and progressive organ damage. Sickle cell crisis refers to acute complications requiring emergency care.

Types of Crises

TypeMechanismKey Features
Vaso-occlusive (Pain) CrisisMicrovascular occlusionMost common; bone, chest, abdomen pain
Acute Chest SyndromePulmonary vaso-occlusion ± infectionFever, new infiltrate, respiratory symptoms
Aplastic CrisisParvovirus B19 → marrow suppressionSevere anemia, low reticulocytes
Splenic SequestrationBlood pooling in spleenRapid anemia, splenomegaly, shock
Hemolytic CrisisAccelerated hemolysisWorsening anemia, high LDH/bilirubin
StrokeCerebral vaso-occlusion or hemorrhageFocal deficits, altered consciousness
PriapismPenile vascular occlusionPainful sustained erection > hours

Epidemiology

  • SCD prevalence: 100,000+ in US; 1 in 365 African American births
  • Life expectancy: 40-60 years (improved with modern care)
  • ED visits: SCD patients have high ED utilization
  • ACS is leading cause of death: And second most common cause of hospitalization
  • Stroke incidence: 11% by age 20 (without prevention)

Genotypes

GenotypeDescriptionSeverity
HbSSHomozygous (Sickle Cell Anemia)Most severe
HbSCCompound heterozygous (S + C)Moderate severity
HbS-β0 thalassemiaS + β0 thalSevere
HbS-β+ thalassemiaS + β+ thalVariable
HbASSickle cell traitUsually asymptomatic

Pathophysiology

Mechanism of Sickling

  1. Deoxygenation: Low O2 tension triggers HbS polymerization
  2. Polymer formation: HbS molecules aggregate into rigid polymers
  3. Cell deformation: RBCs become rigid, sickle-shaped
  4. Vaso-occlusion: Sickled cells obstruct microvasculature
  5. Ischemia-reperfusion injury: Tissue damage, inflammation
  6. Chronic hemolysis: RBC destruction → anemia

Triggers for Sickling

CategoryTriggers
HypoxiaAltitude, pneumonia, sleep apnea
DehydrationVolume depletion
AcidosisInfection, DKA
ColdVasoconstriction
StressSurgery, trauma, psychological
InfectionMost common trigger

Acute Chest Syndrome Pathophysiology

  • Pulmonary vaso-occlusion
  • Fat embolism from bone marrow infarction
  • Infection (bacterial, viral, atypical)
  • V/Q mismatch, hypoxemia, further sickling
  • Can rapidly progress to respiratory failure

Chronic Organ Damage

OrganManifestation
SpleenAutosplenectomy (functional asplenia)
BrainStroke, silent infarcts, cognitive impairment
KidneysChronic kidney disease, papillary necrosis
HeartPulmonary hypertension, cardiomyopathy
BonesAvascular necrosis, osteomyelitis
EyesProliferative retinopathy
LiverIron overload, intrahepatic cholestasis

Clinical Presentation

Vaso-Occlusive (Pain) Crisis

Typical Presentation:

Physical Examination:

Acute Chest Syndrome

Diagnostic Criteria:

Symptoms:

Stroke

Presentation:

Other Presentations in SCD

ConditionClues
Fever (>8.5°C)Medical emergency—functional asplenia
PriapismPainful erection > hours
Splenic sequestrationLUQ fullness, falling Hgb, hypovolemia
Aplastic crisisSevere anemia, low reticulocytes, parvovirus contact
Bone infarction vs osteomyelitisDistinguish: Osteomyelitis has focal warmth, MRI helps

History

Key Questions:


Severe pain in bones (back, long bones, ribs), abdomen, chest
Common presentation.
Sudden onset, often with identifiable trigger
Common presentation.
May last hours to days
Common presentation.
Often similar pattern to prior crises
Common presentation.
Red Flags

Life-Threatening Complications

FindingConcernAction
New pulmonary infiltrate + respiratory symptomsAcute Chest SyndromeO2, transfusion, antibiotics, ICU
Fever >8.5°CSepsis in asplenic patientBlood cultures, empiric antibiotics
Neurological deficitStrokeEmergent imaging, exchange transfusion
Rapid drop in Hgb + splenomegalySplenic sequestrationUrgent transfusion
Hgb drop + low reticulocytesAplastic crisisTransfusion
Priapism > hoursIschemic priapismUrology, aspiration, phenylephrine
Multi-organ failureSevere crisisExchange transfusion, ICU

Differential Diagnosis

Pain Crisis Mimics

DiagnosisFeatures
OsteomyelitisFever, focal warmth; Salmonella common in SCD
Avascular necrosisChronic hip/shoulder pain
CholecystitisRUQ pain, pigment gallstones common
AppendicitisRLQ pain, anorexia
Pulmonary embolismDyspnea, pleuritic chest pain
Myocardial infarctionChest pain, ECG changes
PneumoniaCough, fever, infiltrate

Acute Chest Syndrome vs Pneumonia vs PE

  • Often cannot distinguish clinically
  • Treat empirically for all
  • ACS may evolve from pain crisis

Diagnostic Approach

Laboratory Studies

TestPurposeExpected Finding
CBCAnemia, WBCBaseline Hgb usually 6-9 g/dL (SS)
Reticulocyte countMarrow responseElevated (hemolytic); low (aplastic crisis)
Type and screenTransfusion prepExtended phenotype matching
Blood culturesIf febrileRule out bacteremia
BMPRenal functionMay have baseline CKD
LFTs, bilirubinHemolysis, liver involvementElevated indirect bilirubin
LDHHemolysis markerElevated at baseline
UrinalysisUTI, hemoglobinuriaHematuria may be chronic
ABGHypoxemia, acidosisIf respiratory distress
HbS percentageFor transfusion targetUsually by Hgb electrophoresis

Imaging

StudyIndication
CXRFever, respiratory symptoms (ACS)
CT HeadNeurological deficit (stroke)
MRI BrainIf CT negative but clinical concern
CT Angio ChestPE if suspected (distinguish from ACS)
Abdominal imagingIf concern for cholecystitis, splenic sequestration

Special Considerations

  • Know patient's baseline Hgb
  • Extended RBC phenotype matching (reduces alloimmunization)
  • Higher incidence of iron overload (if chronically transfused)

Treatment

Principles of Management

  1. Treat pain aggressively: Opioids are appropriate
  2. Hydration: IV fluids (avoid overload)
  3. Oxygen: Only if hypoxic (avoid hyperoxia)
  4. Identify and treat triggers: Infection, dehydration
  5. Transfusion: Based on indication
  6. Early recognize ACS and stroke: Life-threatening

Pain Crisis Management

Analgesia:

DrugDoseNotes
Morphine0.1-0.15 mg/kg IV q2-3hStandard opioid
Hydromorphone0.015-0.02 mg/kg IV q2-3hAlternative
Ketorolac15-30 mg IV × 5 days maxAdjunctive (caution renal)
Acetaminophen1g PO/IV q6hOpioid-sparing

Pain Assessment:

  • Treat to patient's reported pain level
  • Use patient's known effective regimen
  • PCA may be needed for severe pain
  • Reassess frequently

Supportive Care:

MeasureDetails
IV FluidsNS or D5-1/2NS at 1-1.5× maintenance; avoid overhydration
Incentive spirometryPrevent atelectasis and ACS (q2h while awake)
WarmingAvoid cold
DVT prophylaxisIf hospitalized
MonitoringVitals, SpO2, pain score

Acute Chest Syndrome

Treatment Steps:

InterventionDetails
OxygenMaintain SpO2 ≥95%
AnalgesiaContinue pain management
AntibioticsCeftriaxone + azithromycin/fluoroquinolone (cover atypicals)
BronchodilatorsIf wheezing
Simple transfusionIf Hgb drop or moderate symptoms
Exchange transfusionIf severe (PaO2 <60 on room air, deteriorating, multi-lobar)
ICU admissionIf severe, worsening, or on high O2

Transfusion Targets:

  • Simple transfusion: Raise Hgb to 10 g/dL (not higher—hyperviscosity)
  • Exchange transfusion: Target HbS <30%

Fever/Sepsis

All febrile SCD patients:

  • Blood cultures
  • Empiric antibiotics ASAP (ceftriaxone 2g IV)
  • Cover encapsulated organisms (Strep pneumo, H. flu, Salmonella)
  • Low threshold for admission

Stroke

Treatment:

InterventionDetails
Emergent exchange transfusionTarget HbS <30%, Hgb ~10
Supportive careO2, IV fluids, monitoring
Avoid thrombolyticsLimited data; generally not used
Neurology consultationImmediate
MRI/MRAAssess extent, vascular involvement

Priapism

Ischemic Priapism (>4 hours):

StepDetails
AnalgesiaPain control
AspirationBy urology; aspirate corpora cavernosa
InjectionPhenylephrine (dilute) into corpora
If refractorySurgical shunt
Exchange transfusionIf not responding

Splenic Sequestration

Treatment:

  • Emergent transfusion (may need large volumes)
  • Fluid resuscitation
  • ICU admission if hemodynamically unstable
  • Splenectomy after stabilization (if recurrent)

Aplastic Crisis

Treatment:

  • Transfusion to correct anemia
  • Usually self-limited (parvovirus B19)
  • Isolation (contagious to others, especially pregnant women)
  • Monitor for recovery (reticulocyte count)

Disposition

ICU Admission

  • Severe ACS (high O2 requirement, worsening)
  • Stroke
  • Multi-organ failure
  • Hemodynamic instability (sepsis, splenic sequestration)
  • Exchange transfusion in progress

Floor Admission

  • Pain crisis requiring IV opioids
  • Mild/moderate ACS
  • Fever requiring IV antibiotics
  • Aplastic crisis needing transfusion

Discharge Criteria

  • Pain controlled on oral medications
  • Afebrile
  • Adequate oxygenation
  • Able to maintain hydration
  • Close follow-up arranged

Follow-Up

SituationFollow-Up
Pain crisisHematology within 1-2 weeks
ACS (mild, discharged)Hematology within 1 week
Post-transfusionHematology 1-2 weeks (HbS level)
StrokeNeurology, chronic transfusion program

Patient Education

Condition Explanation

  • "Sickle cell disease causes your red blood cells to become stiff and sticky, which can block blood flow and cause pain."
  • "We are giving you strong pain medicine and fluids to help with this crisis."
  • "It's important to recognize the signs of serious complications like chest problems or fever."

Prevention

  • Stay hydrated
  • Avoid extreme temperatures, high altitude
  • Manage stress
  • Take hydroxyurea as prescribed
  • Get vaccinations (pneumococcal, meningococcal, flu)
  • Prompt medical attention for fever

Warning Signs

  • Fever (>38.5°C)
  • Chest pain, difficulty breathing
  • Severe headache, vision changes, weakness/numbness
  • Abdominal swelling
  • Priapism (erection >4 hours)

Special Populations

Pregnancy

  • High-risk pregnancy
  • Increased frequency of crises
  • Risk of preterm labor, IUGR
  • Hydroxyurea contraindicated
  • May need prophylactic transfusions
  • Obstetrics and hematology co-management

Pediatric

  • Higher risk of splenic sequestration
  • Stroke prevention (transcranial Doppler screening)
  • Penicillin prophylaxis until age 5
  • Spleen may be palpable (before autoinfarction)

Surgical Patients

  • Preoperative transfusion to Hgb ~10
  • Aggressive hydration, oxygenation, warming
  • Pain management planning

Sickle Cell Trait (HbAS)

  • Usually asymptomatic
  • Rare complications: Splenic infarct at altitude, hematuria
  • Do not treat like SCD

Quality Metrics

Performance Indicators

MetricTargetRationale
Time to first dose of analgesia<30 minutesTreat pain rapidly
Blood cultures before antibiotics (if febrile)100%Adequate workup
Incentive spirometry documented100% of admittedPrevent ACS
Transfusion with extended phenotype matching100%Prevent alloimmunization
Hematology follow-up arranged100%Ongoing care

Documentation Requirements

  • Pain score and treatment response
  • Baseline hemoglobin
  • Prior complications (ACS, stroke)
  • Opioid history and regimen
  • Transfusion history
  • HbS level (if available)

Key Clinical Pearls

Diagnostic Pearls

  • Pain crisis is a diagnosis of exclusion: Rule out infection, ACS, etc.
  • ACS may evolve from pain crisis: Repeat CXR if worsening
  • Fever = emergency in SCD: Functional asplenia
  • Low reticulocytes with anemia = aplastic crisis: Think parvovirus
  • Know the patient's baseline Hgb: Drop of >1-2 g/dL is significant
  • Stroke can be subtle: Any neuro change warrants imaging

Treatment Pearls

  • Do not undertreat pain: Opioids are appropriate
  • Transfuse to Hgb ~10, not higher: Hyperviscosity risk
  • Exchange transfusion for severe ACS/stroke: Target HbS <30%
  • Incentive spirometry prevents ACS: 10 breaths q2h
  • Cover atypical organisms in ACS: Chlamydia, Mycoplasma
  • Don't give supplemental O2 unless hypoxic: May suppress erythropoiesis

Disposition Pearls

  • Most pain crises need admission: Unless rapid resolution
  • Low threshold for ICU with ACS: Can deteriorate quickly
  • Stroke requires immediate hematology and exchange: Do not delay
  • Ensure sickle cell follow-up: Chronic disease management reduces crises

References
  1. Yawn BP, et al. Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members. JAMA. 2014;312(10):1033-1048.
  2. Howard J, et al. Guideline on the management of acute chest syndrome in sickle cell disease. Br J Haematol. 2015;169(4):492-505.
  3. Rees DC, et al. Sickle-cell disease. Lancet. 2010;376(9757):2018-2031.
  4. DeBaun MR, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease. Blood Adv. 2020;4(8):1554-1588.
  5. Chou ST, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327-355.
  6. Glassberg J. Evidence-based management of sickle cell disease in the emergency department. Emerg Med Pract. 2011;13(8):1-20.
  7. Brandow AM, DeBaun MR. Key Components of Pain Management for Children and Adults with Sickle Cell Disease. Hematol Oncol Clin North Am. 2018;32(3):535-550.
  8. UpToDate. Acute vaso-occlusive pain management in sickle cell disease. 2024.

At a Glance

EvidenceStandard
Last UpdatedRecently

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines